Elusys Therapeutics, Inc.

53 articles about Elusys Therapeutics, Inc.

• Elusys Therapeutics, Inc.' Anthrax Therapeutic, Anthim(TM), Granted FDA Orphan Drug Designation

  6/21/2006

• MedImmune, Inc. Licenses Elusys Therapeutics, Inc.' Technology For Use In Developing New Therapies Targeting Infectious Disease

  4/20/2006

• Elusys Therapeutics, Inc. Successfully Completes Human Clinical Study Of Anthrax Therapeutic, Anthim(TM)

  3/28/2006

• Elusys Therapeutics, Inc.' Anthrax Drug, Anthim(TM), Superior To Antibiotic As A Post-Exposure Monotherapy

  2/16/2006

• Elusys Therapeutics, Inc. To Present New Post Exposure Efficacy Data For Antrax Therapeutic, Anthim(TM), At ASM Biodefense Research Meeting

  2/13/2006

• Elusys Therapeutics, Inc. Presents Data On Therapeutic For Staphylococcus Aureus At ICAAC

  12/19/2005

• Elusys Therapeutics, Inc. Announces Two Presentations At ICAAC, Including A Late-Breaker On ETI-211 Targeting Methicillin Resistant Staphylococcus Aureus

  12/14/2005

• Threat Of Anthrax Attack Creates $200M Jackpot

  10/24/2005

• Elusys Therapeutics, Inc. Awarded An Additional $5.4 Million From The U.S. Government For Continued Development Of Anthim(TM)

  8/3/2005

• Elusys Therapeutics, Inc. Submits IND To Initiate Human Studies Of Anthrax Drug; Major Milestone In Company's Development Of Anthim

  2/28/2005

• Elizabeth Posillico Named President Of Elusys Therapeutics, Inc.

  1/31/2005

• Elusys Drug Demonstrates Survival Benefits When Given After Anthrax Exposure

  11/17/2004

• EluSys Therapeutics Presents Data On Anthrax Antibody At American Society for Microbiology's Biodefense Research Meeting

  3/9/2004